scholarly journals TO EVALUATE THE EFFICACY OF GUDUCHYADI YOGA IN THE MANAGEMENT OF RAKTACHAPADHIKYATA OR ESSENTIAL HYPERTENSION-A RANDOMIZED CONTROLLED CLINICAL TRIAL

2020 ◽  
pp. 13-20
Author(s):  
Nitish Pathania ◽  
Umesh C C ◽  
Gopala Krishna G ◽  
Monika Pathania
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
High Blood Pressure ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Standard Drug ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Group B ◽  
Trial Drug

Hypertension is the most pressing public health challenges. It is estimated that approximately 1 billion people are suffering from high blood pressure and the numbers are to increase to 2.5 billion by 2025. Raktachaapadhikya is the coined term for increased blood pressure given by recent authors where it can be understood as the pathology of Vyanvayu. The usage of Guduchyadi Yoga has been highlighted in the classics of Ayurveda for targeting the Hridaya sthitha vayu, which has not been evaluated yet. Aim: To evaluate and compare the efficacy of Navahridaya Kalpa (standard drug) and Guduchyadi Yoga (trial drug) for management of essential hypertension. Materials and Methods: A simple randomized controlled clinical study where 40 patients were equally divided as group A: Navahridaya kalpa (standard drug) and Group B: Guduchyadi yoga (trial drug) for a period of one month. Observations and results: The study result revealed that both the groups were beneficial in reducing high blood pressure however with no statistically significant difference found between the groups with p value being 0.339 for standard drug and 0.363 for trial drug. The group B was also found to be effective in reducing systolic blood pressure of stage I hypertension with p value .044 on comparing between the groups. Conclusion: The Guduchyadi yoga acts as Rasayana with the property of rejuvenation and antihypertensive which will check the high blood pressure at a very minimum cost without having any major adverse effects in the patients and hence can be advocated for use on a daily a basis.

The effect of Gokshura Churna over Tilanalakshara Yoga in the management of Mutrashmari - A Randomized Comparative Clinical Study

2018 ◽  
Vol 3 (5) ◽  
Author(s):  
Dr. Anil M. Sanshi ◽  
Dr.Pallavi A. Hegde
Keyword(s):  
Abdominal Pain ◽  
Renal Calculi ◽  
Renal Calculus ◽  
P Value ◽  
Standard Group ◽  
Standard Drug ◽  
Female Ratio ◽  
Comparative Clinical Study ◽  
Group B ◽  
Trial Drug

Background: Mutrashmari is a stone like structure anywhere in the Mutravaha Srothas which can be compared with renal calculi and one among the Astamahagada, clinical features as renal angle pain, haematuria, pyuria and dysuria. Peak age is 3rd to 5th decade while majority of patients report regarding onset of disease in 2nd decade of life and male to female ratio is 3:1. Objectives: To compare the effect of Gokshura Churna over Tilanalakshara Yoga in the management of Mutrashmari with special reference to Renal calculi. Materials and Methods: 30 patients were selected on the basis of inclusion criteria and divided into 2 groups with 15 patients in each group by chit method. Group A was treated with standard drug Tilanalakshara Yoga and Group B was traeted with trial drug Gokshura Churna. Results: It was found that standard group reduced the abdominal pain by 85.1%, dysuria by 89.4%, renal angle tenderness 88.4%, haematuria 100%, pyuria 100%, size of renal calculus 41.9% by 21st day of treatment. In study group it was observed that abdominal pain reduced by 92%, dysuria 96.1%, renal angle tenderness 91.6%, haematuria 100%, pyuria 100% and size of renal calculus 48.5% by 21st day of treatment. Conclusion: This assessment showed Gokshura Churna had significant result over Tilanala Kshara Yoga in both subjective and objective parameters with P value less than 0.0001.

scholarly journals A CLINICAL EVALUATION OF ANTIMICROBIAL ACTIVITY OF GOMUTRA ARKA IN DUSTA VRANA

2020 ◽  
pp. 27-35
Author(s):  
Manish Kumar Singh ◽  
P. Ramesh Bhat ◽  
Sweta Tyagi
Keyword(s):  
Antimicrobial Activity ◽  
Antimicrobial Agents ◽  
Povidone Iodine ◽  
Low Cost ◽  
P Value ◽  
Standard Drug ◽  
Classical Formulation ◽  
Group A ◽  
Group B ◽  
Trial Drug

Vrana chikitsha is very significant in field of Shalya tantra. Healing of Vrana is depends on many factors. Among them growth of microorganism play essential role to slow the process of healing. In Dusta Vrana to improve the healthy granulation and to reduce the colony count of microorganism specific Krimghna dravya is required for that in Shasthi upkrama under Krimighna karma Gomutra Arka is advised. Which has additional property of Lekhana and Ropana. Gomutra Arka is given importance in many oral classical formulation of Ayurveda to treat the Krimi, which is not evaluated for local application on Dusta Vrana yet. Materials and Methods: A simple randomized controlled clinical study where 50 patients were equally divided as group A: Gomutra Arka (trial drug) and Group B: Povidone-iodine (standard drug) for 14 days. Observations and results: The study result revealed that Gomutra Arka proved to be better Antimicrobial agents than povidone-iodine with a highly significant p-value of 0.04 in comparison to 0.68. It was also established in the study that 10mlGomutra Arka proved to be more effective on different microorganisms that are Staphylococcus Aureus, Pseudomonas Aeruginosa, Shigella, Salmonella, E. Coli, and Candida Albicans. Conclusion: The Gomutra Arka acts as an antimicrobial agent due to its property like Katu tikta kashya rasa which are Krimighna in nature by this inhibition of microorganism could happen also due to the Ushna tikshna and Kshara guna gives unfavorable environment for bacterial growth. The presence of constituents like copper, aurum, urea, ammonia further helps in antimicrobial activity. Therefore, Gomutra Arka can be used in regular practice as its available at a low cost, affordable and the study proves its efficiency over the Povidone-iodine controlled group.

scholarly journals Randomized Controlled Clinical Trial Comparing Transurethral Eneucleation and Resection of Prostate and Trans-urethral Resection of Prostate in the Management of Benign Prostatic Hyperplasia

2017 ◽  
Vol 7 (3) ◽  
pp. 216-220
Author(s):  
Md Mehedi Hasan ◽  
Samira Rahat Afroze ◽  
Muhammad Abdur Rahim ◽  
Muhammad Abdus Salam
Keyword(s):  
Controlled Trial ◽  
Ethical Review ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Transurethral Resection Of Prostate ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Group A ◽  
The Mean ◽  
Group B

Background: Transurethral resection of prostate (TURP) is the predominant surgical procedure for benign prostatic hypertension (BPH) but is not devoid of complications like capsular perforation, drop in Hb%, drop in Na+, residual adenoma; hence endeavors are evolving to combat such complications. A newer technique transurethral enucleation and resection of prostate (TUERP) has been devised to solve these problems. This study was designed to compare the safety and the efficacy of newer technique, TUERP with widely practiced TURP Methods: This randomized controlled trial was done at BSMMU, after getting ethical approval from the ethical review committee of the institute, from January to October, 2009. A total of 60 BPH patients were purposively enrolled in this study, after obtaining informed written consent and they were randomized as control, Group A (30 patients, underwent TURP) and experimental group, Group B (30 patients, underwent TEURP).Results: The mean preoperative Hb% level of Group A was 15.1 gm% (SD ± 0.5) and perioperative Hb% level was 13.04 gm% (SD ± 6.06). There was significant difference (P <0.05). The mean preoperative Hb% of Group B was 15.2 gm% (SD ± 0.5) and perioperative Hb% was 15.2 gm% (SD ± 0.48). There was no difference (P >0.05). The mean preoperative Na + of Group A was 140 mmol/l (SD ± 4.1) and perioperative Na+ was 126 mmol/l (SD ± 6.8). There was significant difference (P<0.01). The mean preoperative Na+ of Group B was 136 mmol/l (SD ± 4) and perioperative Na+ was 136 mmol/l (SD ± 2.70). There was no difference (P >0.05).Conclusion: TUERP eliminates drop in Hb% and Na+which are usual consequences following TURP. Thus TUERP can be advocated in the treatment of BPH as it also allows completeresection down to surgical capsule.Birdem Med J 2017; 7(3): 216-220

scholarly journals Increase of PlGF (Placental Growth Factor) Level After Administration of Dydrogesterone in Pregnancy

KnE Medicine ◽  
2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Dewi Karlina Rusly
Keyword(s):  
Folic Acid ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Before And After ◽  
Group A ◽  
Study Population ◽  
The Mean ◽  
Group B ◽  
In Pregnancy

<p><strong>Aim:</strong> To observe the effect of Dydrogesterone administration in pregnancy on PlGF level</p><p><strong>Methods:</strong> This is a randomized controlled clinical trial. Study population has been divided into two groups. Group A consists of 20 women who receive only Folic acid 5 mg a day for 4 weeks time. Group B consists of 20 women who receive Dydrogesterone 2x10 mg a day and Folic acid 5 mg a day for 4 weeks. PlGF has been measured twice. First measurement was done before drug administration, while the second measurement has been done during 18<sup>th</sup> weeks of pregnancy. The changes on PlGF level before and after treatment from each group has been analyzed using SPSS 17.</p><p><strong>Results:</strong> 40 pregnant women have been recruited for this study. There are no differences based on the patient’s age, number of pregnancy and parity, gestational age and body weight between each group.  The mean levels of PlGF in both groups before intervention shows no significant difference (p = 0091 or p&gt; 0.05), 40.80 pg/mL vs.  25.95 pg / mL. The mean levels of PlGF in group A after 4 weeks administration of Folic acid is 89.60 pg / mL. It shows the escalation of 48.8 pg / mL. The elevation of PlGF level in group A shows significant difference (p = 0.000 or p &lt;0.05) after 4 weeks Folic acid treatment.The mean levels of PlGF in group B after 4 weeks administration of Dydrogesterone and Folic acid is 212.15 pg / mL. It shows the escalation of 186.20 pg / mL. The elevation of PlGF level in group B shows significant difference (p = 0.000 or p &lt;0.05) after 4 weeks Dydrogesterone and Folic acid treatment.</p><p><strong>Conclusion:</strong> Dydrogesterone treatment can increase the level of PlGF.</p>

scholarly journals Role of antihypertensives drugs on proteinuria in patients with chronic kidney disease and hypertension

2017 ◽  
Vol 6 (10) ◽  
pp. 2522
Author(s):  
Ritu Bala ◽  
Harminder Singh ◽  
. Rupali ◽  
Kuhu Verma
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Heart Rate ◽  
P Value ◽  
Biochemical Tests ◽  
Mortality And Morbidity ◽  
Significant Difference ◽  
Group A ◽  
Group B

Background: Hypertension is the most prevalent cardiovascular disease and the relevant data suggest that the burden, risk factors and co-morbidities associated with the essential hypertension is increasing with every passing day. It is one of the major chronic diseases resulting in high mortality and morbidity in today’s world. Aim: The aim of the study was to compare effects of cilnidipine and amlodipine on the blood pressure (BP), heart rate and proteinuria among patients of hypertension with chronic kidney disease.Methods: 100 patients were included in this study. Patients were randomly assigned into two groups Group A and Group B (50 each). Group A: Patients received Cilnidipine (5-10mg/day). Group B: Patients received amlodipine (5-10mg/day).Results: No significant difference in SBP, DBP, MBP and proteinuria while comparing both the groups of patients taking cilnidipine and amlodipine at baseline i.e. 0 to 12 week, 12 to 24 weeks and 0 to 24 weeks. Cilnidipine caused decrease in HR 0 to 12 week (p value 0.001), 12 to 24 weeks (p value 0.001) and 0 to 24 weeks (p value 0.0001). Amlodipine had increased heart rate from baseline to 12 weeks (p value 0.0001), 12 to 24 weeks (p value 0.051) and 0 to 24 weeks (p value 0.001). No significant difference was seen in any biochemical readings.Conclusions: There was a significant change in all the parameters including BP, heart rate, proteinuria and other biochemical tests when they compared within the group but no significant difference while comparing both the groups.

scholarly journals Design and Implementation of Heart Beat Monitor System

2021 ◽  
pp. 68-87
Author(s):  
F. T. Oyediji ◽  
A. O. Aluko ◽  
A. O. Adetunmbi
Keyword(s):  
Blood Pressure ◽  
High Blood Pressure ◽  
Research Work ◽  
Cost Effective ◽  
Electrical Signal ◽  
Heart Beat ◽  
P Value ◽  
Output Section ◽  
Significant Difference ◽  
Level Of Significance

Over the years, the decline of Nigeria’s health-care infrastructure has become alarming. The 2018 annual report of WHO shows that 75% human cardiovascular disease resulted from High Blood pressure. Immediate technical action is needed to alleviate the severity to the barest minimum. This research work presents a designs and implementation of microcontroller based Heart Beat Monitoring System for High Blood Pressure Patients. The developed system consists of three sections which include; Input section consisting of Heart beat sensor that senses and converts the blood pulse from a fingertip into an electrical signal. The sensor thereafter sends the signal into microcontroller, which is the control section that acts and communicates the result through LCD and output section. The displayed results show the beat rate in unit of beat per minute (BPM). The developed system was evaluated and demonstrated with two other standard devices namely: Pulse Oximeter and Digital Arm Cuff using a one-way analysis of variance (ANOVA) to determine its level of significance. The P Value of 0.519049 was found significant at 0.05 level of significance. Additionally, the results indicate that there is no significant difference among the three devices. It was concluded the designed device is more cost effective, user friendly and easily assembled due availability of needed materials in contrast with the other standard devices.

scholarly journals The effect of granisetron, ondansetron, and pethidine in preventing postoperative shivering: controlled clinical trial

2019 ◽  
Author(s):  
Masood Entezariasl ◽  
Hamed Zandian ◽  
Khatereh Isazadehfar
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
P Value ◽  
Anesthesia Induction ◽  
Central Temperature ◽  
Significant Difference ◽  
The Mean ◽  
The Difference ◽  
Peripheral Temperature

Abstract Background: recently, use of HT35 receptor antagonists to prevent postoperative shivering has attracted a great deal of attention. Therefore, the present study was conducted with the aim of investigating the effectiveness of granisetron as an HT35 antagonist when compared with ondansetron and pethidine in preventing postoperative shivering. Methods: in this triple blind random clinical trial study, 90 patients 18-50 years of age with ASA Class I and II undergoing general anesthesia were randomly assigned into one of the three drug groups: O (4-mg ondansetron), G (40 μg/kg of granisetron), and P (25 mg pethidine), immediately before induction of anesthesia. After anesthesia induction, at the end of the surgery, after the entrance and after leaving the recovery state, central temperature, peripheral temperature, systolic blood pressure, diastolic blood pressure, heart rate, and shivering were measured and recorded. P-value less than 0.05 was considered statistically significant. Results: in the pethidine, ondansetron, and granisetron groups, 4 (13.3%), 3 (10%), and 10 (33.3%) of patients experienced shivering during recovery, where the difference between the ondansetron and granisetron groups was significant (p-value=0.02). The variations in the mean arterial pressure during the investigation stages were not significant only in the ondansetron group (p>0.05). At the beginning of recovery, the reduction of peripheral temperature was significantly lower in the ondansetron group (p<0.05), while reduction of the central temperature was higher in the granisetron group (p<0.05). By the end of the recovery, the changes in the peripheral temperature across the three groups were consistent with the changes at the beginning of recovery, but no significant difference was observed variations of the central temperature across the three groups. Conclusion: Granisetron was not found to be much effective in preventing postoperative shivering. Ondansetron and pethidine were equally effective in preventing postoperative shivering. Ondansetron also causes less hemodynamic changes compared to other drugs, while granisetron is more effective in terms of preventing nausea and vomiting

scholarly journals Impact of the 25-Hydroxycholecalciferol Concentration and Vitamin D Deficiency Treatment on Changes in the Bone Level at the Implant Site during the Process of Osseointegration: A Prospective, Randomized, Controlled Clinical Trial

2021 ◽  
Vol 10 (3) ◽  
pp. 526
Author(s):  
Jakub Kwiatek ◽  
Aleksandra Jaroń ◽  
Grzegorz Trybek
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Group A ◽  
Bone Level ◽  
Group B ◽  
Implant Treatment ◽  
Correct Level ◽  
25 Hydroxycholecalciferol

Introduction: The most important factor which is responsible for the positive course of implant treatment is the process of osseointegration between the implant structure and the host’s bone tissue. The aim of this study was to assess what effect the 25-hydroxycholecalciferol concentration and vitamin D deficiency treatment have on changes in the bone level at the implant site during the process of osseointegration in the mandible. Materials and Methods: The study was with 122 people qualified for implant surgery, who were assigned to three research groups (A, B, and C). Laboratory, clinical, and radiological tests were performed on the day of surgery, and after 6 and 12 weeks. The bone level in the immediate proximity of the implant was determined by radiovisiography (RVG). Results: The bone level after 12 weeks in Groups B and C was significantly higher than after 6 weeks. The bone level in the study Group B was significantly higher than in Group A. The study showed that the higher the levels of 25-hydroxycholecalciferol were observed on the day of surgery, the higher was the level of bone surrounding the implant after 6 and 12 after surgery. Conclusion: The correct level of 25-hydroxycholecalciferol on the day of surgery and vitamin D deficiency treatment significantly increase the bone level at the implant site in the process of radiologically assessed osseointegration.

Sign in / Sign up

Export Citation Format

Share Document